359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Antonio Pousa; Enriqueta Felip; Martin Forster; Bernard Doger; Patricia Roxburgh; Pawan Bajaj; Julio Peguero; Enric Carcereny; Matthew Krebs; Christian Mueller; Frederic Triebel

doi:10.1136/jitc-2021-SITC2021.359

359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

Antonio Pousa, Enriqueta Felip, Martin Forster, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero, Enric Carcereny, Matthew Krebs, Christian Mueller, Frederic Triebel

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	A386-A386
Journal	Journal for ImmunoTherapy of Cancer
Volume	9
DOIs	https://doi.org/10.1136/jitc-2021-SITC2021.359
Publication status	Published - 1 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/jitc-2021-SITC2021.359

Cite this

Pousa, A., Felip, E., Forster, M., Doger, B., Roxburgh, P., Bajaj, P., Peguero, J., Carcereny, E., Krebs, M., Mueller, C., & Triebel, F. (2021). 359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC). Journal for ImmunoTherapy of Cancer, 9, A386-A386. https://doi.org/10.1136/jitc-2021-SITC2021.359

@article{4f1547f6488046688672eef92cf102bc,

title = "359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)",

author = "Antonio Pousa and Enriqueta Felip and Martin Forster and Bernard Doger and Patricia Roxburgh and Pawan Bajaj and Julio Peguero and Enric Carcereny and Matthew Krebs and Christian Mueller and Frederic Triebel",

year = "2021",

month = nov,

day = "1",

doi = "10.1136/jitc-2021-SITC2021.359",

language = "English",

volume = "9",

pages = "A386--A386",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "Springer Nature",

}

Pousa, A, Felip, E, Forster, M, Doger, B, Roxburgh, P, Bajaj, P, Peguero, J, Carcereny, E, Krebs, M, Mueller, C & Triebel, F 2021, '359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)', Journal for ImmunoTherapy of Cancer, vol. 9, pp. A386-A386. https://doi.org/10.1136/jitc-2021-SITC2021.359

359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC). / Pousa, Antonio; Felip, Enriqueta; Forster, Martin et al.
In: Journal for ImmunoTherapy of Cancer, Vol. 9, 01.11.2021, p. A386-A386.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

AU - Pousa, Antonio

AU - Felip, Enriqueta

AU - Forster, Martin

AU - Doger, Bernard

AU - Roxburgh, Patricia

AU - Bajaj, Pawan

AU - Peguero, Julio

AU - Carcereny, Enric

AU - Krebs, Matthew

AU - Mueller, Christian

AU - Triebel, Frederic

PY - 2021/11/1

Y1 - 2021/11/1

U2 - 10.1136/jitc-2021-SITC2021.359

DO - 10.1136/jitc-2021-SITC2021.359

M3 - Meeting Abstract

SN - 2051-1426

VL - 9

SP - A386-A386

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

ER -